This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Authoring team

  • mild heart failure has an annual mortality of not more than 10%
  • severe heart failure has an annual mortality of 50%
  • B-type natriuretic peptide (BNP):
    • higher concentrations of BNP or its precursor form, N-terminal pro-brain natriuretic peptide, are consistently associated with increased risk of death and cardiovascular events (1)
  • a study of over 5 million people examined long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003 (2)
    • age-adjusted first hospitalization rates for heart failure (HF) (per 100 000; 95% CI in parentheses)
      • rose from 124 (119 to 129) in 1986 to 162 (157 to 168) in 1994 and then fell to 105 (101 to 109) in 2003 in men;
      • in women, they rose from 128 (123 to 132) in 1986 to 160 (155 to 165) in 1993, falling to 101 (97 to 105) in 2003
    • case-fatality rates fell steadily over the period
      • adjusted 30-day case-fatality rates fell after discharge (adjusted odds [2003 versus 1986] 0.59 [95% CI 0.45 to 0.63] in men and 0.77 [95% CI 0.67 to 0.88] in women)
      • adjusted 1- and 5-year survival improved similarly
        • median survival increased from 1.33 to 2.34 years in men and from 1.32 to 1.79 years in women.

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.